Skip to content

    Recently Viewed


      Home / Media Center / Press releases /
      Medical technologies

      Medical technologies

      Johnson & Johnson MedTech working with NVIDIA to scale AI for surgery

      Johnson & Johnson MedTech is working with NVIDIA on how its technologies can accelerate secure, real-time analysis of surgical data at the edge Johnson & Johnson MedTech will enable AI-based model development and application deployment, providing a path to scale within its connected digital ecosystem for surgery

      Biosense Webster Announces CE Mark approval in Europe for VARIPULSE™ Pulsed Field Ablation (PFA) Platform

      Regulatory approval for the first fully integrated PFA system with a CARTO-enabled simple and reproducible workflow. Integrated with the world’s leading CARTO™ 3D Cardiac Mapping System for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation (AF). CE Mark follows recent approval of the VARIPULSE™ Platform in Japan.

      Biosense Webster Begins Enrollment of Pivotal Trial Evaluating the Laminar Left Atrial Appendage Elimination Device 

      Investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation 

      Orthopaedic Experts Identify Best Practices for Wound Closure and Dressing Management in Total Knee and Total Hip Arthroplasty

      Studies Published in The Journal of Arthroplasty Feature Consensus from 20 Orthopaedic Surgeons on Surgical Wound Management with the Goal to Reduce Variability and Promote Standardization

      CERENOVUS Launches Next Generation Catheter for Revascularization of Patients with Acute Ischemic Stroke

      Next-generation intermediate catheter, CEREGLIDE™ 71 Intermediate Catheter with TruCourse™, now available across the U.S.

      Biosense Webster Presents Late-Breaking Data from inspIRE and admIRE Clinical Trials at AF Symposium

      Final results from inspIRE study demonstrate 80% freedom from atrial arrhythmia recurrence at 12 months in patients with optimal Pulsed Field Ablation applications First look results from admIRE study suggests similar outcomes

      Biosense Webster Study Supports Low and Zero Fluoroscopy Workflow as Safe, Effective Alternative to Conventional Catheter Ablation

      Retrospective Analysis of Real-World Data Presented as Late-Breaker at 29th Annual International AF Symposium

      Biosense Webster Announces Regulatory Approval of VARIPULSE™ Pulsed Field Ablation (PFA) Platform in Japan

      First regulatory approval for the first-of-its-kind, fully-integrated PFA system with a simple and reproducible workflow Integrated with the world’s leading CARTO™ 3D cardiac mapping system for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation (AFib) First and only PFA system approved in Japan
      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.